Kymera Therapeutics Valuation
| KYMR Stock | USD 32.54 0.67 2.02% |
At this time, the firm appears to be fairly valued. Kymera Therapeutics secures a last-minute Real Value of $32.54 per share. The latest price of the firm is $32.54. Our model forecasts the value of Kymera Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.36, operating margin of (10.92) %, and Shares Outstanding of 64.94 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Kymera Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Kymera Therapeutics is based on 3 months time horizon. Increasing Kymera Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Kymera stock is determined by what a typical buyer is willing to pay for full or partial control of Kymera Therapeutics. Since Kymera Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kymera Stock. However, Kymera Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 32.54 | Real 32.54 | Hype 32.54 | Naive 32.4 |
The intrinsic value of Kymera Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kymera Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kymera Therapeutics helps investors to forecast how Kymera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kymera Therapeutics more accurately as focusing exclusively on Kymera Therapeutics' fundamentals will not take into account other important factors: Kymera Therapeutics Total Value Analysis
Kymera Therapeutics is now expected to have valuation of 1.8 B with market capitalization of 2.16 B, debt of 87.76 M, and cash on hands of 392.31 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kymera Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.8 B | 2.16 B | 87.76 M | 392.31 M |
Kymera Therapeutics Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 12.88. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years. Based on the key indicators related to Kymera Therapeutics' liquidity, profitability, solvency, and operating efficiency, Kymera Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Kymera Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kymera Therapeutics has an asset utilization ratio of 4.81 percent. This connotes that the Company is making $0.0481 for each dollar of assets. An increasing asset utilization means that Kymera Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Kymera Therapeutics Ownership Allocation
The majority of Kymera Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kymera Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kymera Therapeutics. Please pay attention to any change in the institutional holdings of Kymera Therapeutics as this could imply that something significant has changed or is about to change at the company.Kymera Therapeutics Profitability Analysis
The company reported the previous year's revenue of 47.07 M. Net Loss for the year was (223.86 M) with loss before overhead, payroll, taxes, and interest of (193.18 M).About Kymera Therapeutics Valuation
The stock valuation mechanism determines Kymera Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Kymera Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kymera Therapeutics. We calculate exposure to Kymera Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kymera Therapeutics's related companies.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people.
Kymera Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Kymera Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 75 M |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.